You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRivaroxaban
Accession NumberDB06228
TypeSmall Molecule
GroupsApproved
DescriptionRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Structure
Thumb
Synonyms
BAY 59-7939
BAY59-7939
Xarelto
External IDs BAY 59-7939
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XareltoTablet, film coated15 mg/1OralAvera Mc Kennan Hospital2015-03-16Not applicableUs
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mg/1OralCardinal Health2011-11-04Not applicableUs
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet10 mgOralBayer2008-09-16Not applicableCanada
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mg/1OralJanssen Pharmaceuticals2011-11-04Not applicableUs
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet15 mgOralBayer2012-01-17Not applicableCanada
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mg/1OralJanssen Pharmaceuticals2011-11-05Not applicableUs
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet20 mgOralBayer2012-01-17Not applicableCanada
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mg/1OralJanssen Pharmaceuticals2011-07-01Not applicableUs
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mg/1OralCardinal Health2011-07-01Not applicableUs
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoKitJanssen Pharmaceuticals2014-09-16Not applicableUs
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated20 mg/1OralCardinal Health2011-11-05Not applicableUs
XareltoTablet, film coated15 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag  2008-09-30Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
XareltoBayer
Categories
UNII9NDF7JZ4M3
CAS number366789-02-8
WeightAverage: 435.881
Monoisotopic: 435.065569098
Chemical FormulaC19H18ClN3O5S
InChI KeyKGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
IUPAC Name
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
SMILES
ClC1=CC=C(S1)C(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Pharmacology
IndicationRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
Structured Indications
PharmacodynamicsRivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.
Mechanism of actionRivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
TargetKindPharmacological actionActionsOrganismUniProt ID
Coagulation factor XProteinyes
antagonist
HumanP00742 details
Related Articles
AbsorptionFollowing oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.
Volume of distribution

The steady state Vd is 50 L

Protein bindingPlasma protein binding is about 92% to 95%
Metabolism

Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of eliminationApproximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.
Half lifeThe terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.
Clearance

Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.

ToxicityExcessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Rivaroxaban.Approved, Investigational
AbciximabAbciximab may increase the anticoagulant activities of Rivaroxaban.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Rivaroxaban.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Rivaroxaban.Approved
AcetaminophenThe serum concentration of Rivaroxaban can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Rivaroxaban.Approved
AfatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Rivaroxaban can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Rivaroxaban can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Rivaroxaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Rivaroxaban.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Rivaroxaban.Approved
AmantadineThe serum concentration of Rivaroxaban can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Rivaroxaban.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Rivaroxaban can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Rivaroxaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
AmiodaroneThe metabolism of Rivaroxaban can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Rivaroxaban.Approved
AmlodipineThe serum concentration of Rivaroxaban can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Rivaroxaban.Approved
AncrodAncrod may increase the anticoagulant activities of Rivaroxaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Rivaroxaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Rivaroxaban.Approved
Antithrombin III humanAntithrombin III human may increase the anticoagulant activities of Rivaroxaban.Approved
ApixabanApixaban may increase the anticoagulant activities of Rivaroxaban.Approved
ApremilastApremilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AstemizoleThe serum concentration of Rivaroxaban can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Rivaroxaban can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Rivaroxaban can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Rivaroxaban.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Rivaroxaban.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Rivaroxaban.Approved
AzithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Rivaroxaban.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Rivaroxaban.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Rivaroxaban.Withdrawn
BenzocaineThe serum concentration of Rivaroxaban can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Rivaroxaban can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Rivaroxaban.Investigational
BexaroteneThe serum concentration of Rivaroxaban can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Rivaroxaban can be increased when it is combined with Biperiden.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BoceprevirThe serum concentration of Rivaroxaban can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Rivaroxaban can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Rivaroxaban can be increased when it is combined with Bosutinib.Approved
BromfenacBromfenac may increase the anticoagulant activities of Rivaroxaban.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.Approved, Investigational
BuprenorphineThe serum concentration of Rivaroxaban can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Rivaroxaban can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Rivaroxaban can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Rivaroxaban.Approved
CaffeineThe serum concentration of Rivaroxaban can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Rivaroxaban can be increased when it is combined with Candesartan.Approved
CangrelorCangrelor may increase the anticoagulant activities of Rivaroxaban.Approved
CaptoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Rivaroxaban can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Rivaroxaban can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Rivaroxaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
CeritinibThe serum concentration of Rivaroxaban can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the anticoagulant activities of Rivaroxaban.Approved
ChloroquineThe serum concentration of Rivaroxaban can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Rivaroxaban.Withdrawn
ChlorpromazineThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Rivaroxaban can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Rivaroxaban can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Rivaroxaban can be increased when it is combined with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Rivaroxaban.Approved
CimetidineThe serum concentration of Rivaroxaban can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Rivaroxaban.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Rivaroxaban can be increased when it is combined with Citalopram.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Rivaroxaban.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Rivaroxaban can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Rivaroxaban can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Rivaroxaban.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Rivaroxaban.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
ClotrimazoleThe metabolism of Rivaroxaban can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Rivaroxaban can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Rivaroxaban can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Rivaroxaban can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Rivaroxaban can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Rivaroxaban.Approved
CrizotinibThe metabolism of Rivaroxaban can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.Approved
DabrafenibThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Rivaroxaban can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Dactinomycin.Approved
DalteparinDalteparin may increase the anticoagulant activities of Rivaroxaban.Approved
DarunavirThe metabolism of Rivaroxaban can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
DaunorubicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Rivaroxaban.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deoxycholic Acid.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.Approved
DesirudinDesirudin may increase the anticoagulant activities of Rivaroxaban.Approved
DesloratadineThe serum concentration of Rivaroxaban can be increased when it is combined with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Rivaroxaban.Investigational
DesogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranDextran may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
Dextran 40Dextran 40 may increase the anticoagulant activities of Rivaroxaban.Approved
DextromethorphanThe serum concentration of Rivaroxaban can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Rivaroxaban can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Rivaroxaban.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Rivaroxaban.Approved
DienogestThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rivaroxaban.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Rivaroxaban.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Rivaroxaban.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Rivaroxaban.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Rivaroxaban.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Rivaroxaban.Approved
DitazoleDitazole may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Rivaroxaban.Approved
DoxazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.Approved
DoxorubicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Rivaroxaban can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Rivaroxaban can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Rivaroxaban can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
DydrogesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Rivaroxaban.Approved
Edetic AcidEdetic Acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.Approved
EfavirenzThe serum concentration of Rivaroxaban can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Rivaroxaban can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Rivaroxaban can be increased when it is combined with Enalapril.Approved, Vet Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Rivaroxaban.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Rivaroxaban.Approved
EnzalutamideThe serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.Approved
EpinastineEpinastine may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Rivaroxaban.Approved
EpoprostenolEpoprostenol may increase the anticoagulant activities of Rivaroxaban.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Rivaroxaban.Approved
ErythromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe metabolism of Rivaroxaban can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Rivaroxaban can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Rivaroxaban.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Rivaroxaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Rivaroxaban.Approved
EstriolEstriol may decrease the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Rivaroxaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Rivaroxaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Rivaroxaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rivaroxaban.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Rivaroxaban.Approved
EtonogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of Rivaroxaban can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Rivaroxaban.Approved
FelodipineThe serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Rivaroxaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
FentanylThe serum concentration of Rivaroxaban can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Rivaroxaban can be increased when it is combined with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Rivaroxaban.Approved
FidaxomicinThe serum concentration of Rivaroxaban can be increased when it is combined with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
FluconazoleThe metabolism of Rivaroxaban can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Rivaroxaban can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Rivaroxaban can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Rivaroxaban can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
FluvoxamineThe metabolism of Rivaroxaban can be decreased when combined with Fluvoxamine.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
FosamprenavirThe metabolism of Rivaroxaban can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Fusidic Acid.Approved
GabexateGabexate may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
GefitinibThe serum concentration of Rivaroxaban can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinGenistein may decrease the anticoagulant activities of Rivaroxaban.Investigational
GestodeneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestrinone.Approved
GlyburideThe serum concentration of Rivaroxaban can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Rivaroxaban can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Rivaroxaban can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Rivaroxaban.Approved
HeparinHeparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Rivaroxaban.Withdrawn
HMPL-004HMPL-004 may increase the anticoagulant activities of Rivaroxaban.Investigational
HydrocortisoneThe serum concentration of Rivaroxaban can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.Approved
IbudilastIbudilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Rivaroxaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Rivaroxaban.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Rivaroxaban can be increased when it is combined with Idelalisib.Approved
IfenprodilIfenprodil may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
ImatinibThe metabolism of Rivaroxaban can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.Approved
IndinavirThe metabolism of Rivaroxaban can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Rivaroxaban can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IsavuconazoniumThe metabolism of Rivaroxaban can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IsradipineThe metabolism of Rivaroxaban can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Rivaroxaban can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Rivaroxaban can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Rivaroxaban can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Rivaroxaban.Experimental
KetamineThe serum concentration of Rivaroxaban can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Rivaroxaban can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Rivaroxaban.Approved
LansoprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Rivaroxaban.Approved
LevofloxacinThe serum concentration of Rivaroxaban can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevothyroxineThe serum concentration of Rivaroxaban can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Rivaroxaban can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Rivaroxaban.Approved
LiothyronineThe serum concentration of Rivaroxaban can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Rivaroxaban can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Rivaroxaban can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Rivaroxaban can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Rivaroxaban can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Rivaroxaban can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
LosartanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Rivaroxaban.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
LuliconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Rivaroxaban can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
MaprotilineThe serum concentration of Rivaroxaban can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Rivaroxaban.Approved
MebendazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved
MefloquineThe serum concentration of Rivaroxaban can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
MeprobamateThe serum concentration of Rivaroxaban can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Rivaroxaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Rivaroxaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Rivaroxaban.Withdrawn
MethadoneThe serum concentration of Rivaroxaban can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Rivaroxaban.Experimental
MetoprololThe serum concentration of Rivaroxaban can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Rivaroxaban can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.Approved, Illicit
MifepristoneThe serum concentration of Rivaroxaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Rivaroxaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Rivaroxaban.Approved
MitomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Rivaroxaban can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Rivaroxaban can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Rivaroxaban.Approved
NadroparinNadroparin may increase the anticoagulant activities of Rivaroxaban.Approved
NafamostatNafamostat may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
NafcillinThe serum concentration of Rivaroxaban can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may increase the anticoagulant activities of Rivaroxaban.Approved
NaltrexoneThe serum concentration of Rivaroxaban can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
NaringeninThe serum concentration of Rivaroxaban can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may increase the anticoagulant activities of Rivaroxaban.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Rivaroxaban.Approved, Withdrawn
NelfinavirThe metabolism of Rivaroxaban can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Rivaroxaban can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Rivaroxaban.Approved
NetupitantThe serum concentration of Rivaroxaban can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Rivaroxaban can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Rivaroxaban can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
NilotinibThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Norethisterone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Rivaroxaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Rivaroxaban can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Rivaroxaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Rivaroxaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
OmeprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Rivaroxaban can be increased when it is combined with Osimertinib.Approved
OxaprozinOxaprozin may increase the anticoagulant activities of Rivaroxaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.Withdrawn
P-NitrophenolThe serum concentration of Rivaroxaban can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Rivaroxaban can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Rivaroxaban.Approved
ParoxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PerindoprilThe serum concentration of Rivaroxaban can be increased when it is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Pethidine.Approved
PhenindionePhenindione may increase the anticoagulant activities of Rivaroxaban.Approved
PhenobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Rivaroxaban.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
PhenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Rivaroxaban.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Rivaroxaban.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Rivaroxaban.Investigational
Platelet Activating FactorThe serum concentration of Rivaroxaban can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Rivaroxaban can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Rivaroxaban can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Rivaroxaban.Approved
PravastatinThe serum concentration of Rivaroxaban can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Rivaroxaban can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Rivaroxaban can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Rivaroxaban can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Rivaroxaban.Approved
PropafenoneThe serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Rivaroxaban can be increased when it is combined with Propranolol.Approved, Investigational
Protein S humanProtein S human may increase the anticoagulant activities of Rivaroxaban.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.Approved
PTC299PTC299 may increase the anticoagulant activities of Rivaroxaban.Investigational
QuercetinThe serum concentration of Rivaroxaban can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinacrine.Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Rivaroxaban.Approved
QuinidineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Rivaroxaban can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Rivaroxaban can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Rivaroxaban can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Rivaroxaban can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Rivaroxaban can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Rivaroxaban can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Rivaroxaban.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Rivaroxaban.Approved
ReviparinReviparin may increase the anticoagulant activities of Rivaroxaban.Approved
RidogrelRidogrel may increase the anticoagulant activities of Rivaroxaban.Approved
RifabutinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rivaroxaban can be increased when it is combined with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Rivaroxaban.Approved
RitonavirThe metabolism of Rivaroxaban can be decreased when combined with Ritonavir.Approved, Investigational
RofecoxibRofecoxib may increase the anticoagulant activities of Rivaroxaban.Investigational, Withdrawn
RolapitantThe serum concentration of Rivaroxaban can be increased when it is combined with Rolapitant.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Rivaroxaban.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Rivaroxaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Rivaroxaban.Approved
SaquinavirThe metabolism of Rivaroxaban can be decreased when combined with Saquinavir.Approved, Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Rivaroxaban.Investigational
ScopolamineThe serum concentration of Rivaroxaban can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Rivaroxaban can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Rivaroxaban.Approved
SertralineThe serum concentration of Rivaroxaban can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Rivaroxaban.Approved, Investigational
SiltuximabThe serum concentration of Rivaroxaban can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Rivaroxaban.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Rivaroxaban.Approved
SirolimusThe serum concentration of Rivaroxaban can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Rivaroxaban can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Rivaroxaban can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Rivaroxaban.Investigational
St. John's WortThe serum concentration of Rivaroxaban can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Rivaroxaban can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Rivaroxaban can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Rivaroxaban.Approved
StreptozocinThe serum concentration of Rivaroxaban can be decreased when it is combined with Streptozocin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Rivaroxaban.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Rivaroxaban.Approved
SulfinpyrazoneThe serum concentration of Rivaroxaban can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Rivaroxaban can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Rivaroxaban.Approved
SulodexideSulodexide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
SumatriptanThe serum concentration of Rivaroxaban can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Rivaroxaban can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Rivaroxaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Rivaroxaban.Approved
TacrineThe serum concentration of Rivaroxaban can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.Approved, Investigational
TacrolimusThe serum concentration of Rivaroxaban can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Rivaroxaban can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe metabolism of Rivaroxaban can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Rivaroxaban can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Rivaroxaban can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Rivaroxaban.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
TerazosinThe serum concentration of Rivaroxaban can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Rivaroxaban can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the anticoagulant activities of Rivaroxaban.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Rivaroxaban.Investigational
TestosteroneThe serum concentration of Rivaroxaban can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Rivaroxaban.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Rivaroxaban.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Rivaroxaban.Approved
TicagrelorThe serum concentration of Rivaroxaban can be increased when it is combined with Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Rivaroxaban.Approved
TinzaparinTinzaparin may increase the anticoagulant activities of Rivaroxaban.Approved
TipranavirThe serum concentration of Rivaroxaban can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Rivaroxaban.Approved
TocilizumabThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Rivaroxaban.Approved
TolvaptanThe serum concentration of Rivaroxaban can be increased when it is combined with Tolvaptan.Approved
TositumomabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Rivaroxaban.Approved
TrazodoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Rivaroxaban.Approved
TrifluoperazineThe serum concentration of Rivaroxaban can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Rivaroxaban can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Rivaroxaban.Approved
TrimethoprimThe serum concentration of Rivaroxaban can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Rivaroxaban.Approved
TroleandomycinThe serum concentration of Rivaroxaban can be increased when it is combined with Troleandomycin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Rivaroxaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Rivaroxaban.Approved, Investigational
VenlafaxineThe metabolism of Rivaroxaban can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Rivaroxaban.Approved
VinblastineThe serum concentration of Rivaroxaban can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Rivaroxaban can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Rivaroxaban can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Rivaroxaban.Approved
VoriconazoleThe metabolism of Rivaroxaban can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Rivaroxaban.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Rivaroxaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Rivaroxaban can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Rivaroxaban.Withdrawn
Food Interactions
  • Food should be taken with the 15 mg and 20 mg tablet. Food increases the bioavailability of the 20 mg dose.
  • Foods with antiplatelet/anticoagulants properties such as horseradish, gingko, ginger, garlic, feverfew
  • St. John's Wort is a CYP3A4 inducer and will decrease levels of rivaroxaban
References
Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, “PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF.” U.S. Patent US20100273790, issued October 28, 2010.

US20100273790
General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [PubMed:18491993 ]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [PubMed:18473863 ]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [PubMed:19846028 ]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [PubMed:19696978 ]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [PubMed:21554163 ]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]
External Links
ATC CodesB01AF01
AHFS Codes
  • 20.12.04.14
PDB EntriesNot Available
FDA labelDownload (537 KB)
MSDSDownload (480 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePediatrics / Thrombosis, Venous1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTherapeutic Equivalency1
1CompletedNot AvailableThrombosis, Venous1
1CompletedOtherBiological Availability1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionProphylaxis of Venous Thromboembolism2
1CompletedTreatmentBioavailability / Healthy Participants / Pharmacokinetics1
1CompletedTreatmentEmbolism, Atrial Fibrillation and Venous Thrombosis2
1CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHealthy Volunteers / Renal Insufficiency1
1CompletedTreatmentThrombosis1
1RecruitingOtherThrombosis1
1RecruitingTreatmentBleeding1
1TerminatedTreatmentGastric Bypass Status1
1, 2RecruitingOtherThromboembolism1
2CompletedPreventionCardiovascular Disease, Coronary Artery Disease1
2CompletedPreventionNonvalvular Atrial Fibrillation3
2CompletedPreventionPrevention / Thromboembolism1
2CompletedPreventionProphylaxis of Venous Thromboembolic Events1
2CompletedPreventionVenous Thromboembolism4
2CompletedTreatmentAcute Coronary Syndromes (ACS)2
2CompletedTreatmentDeep Vein Thrombosis (DVT) / Thrombosis, Venous2
2CompletedTreatmentStroke, Ischemic / Transient Ischemic Attack (TIA)1
2CompletedTreatmentThrombosis, Venous1
2CompletedTreatmentVenous Thromboembolism1
2Enrolling by InvitationTreatmentSickle Cell Anemia / Sickle Cell-Beta0-Thalassemia / Sickle Cell-beta^0^-Thalassemia1
2RecruitingTreatmentValvular Heart Disease1
2RecruitingTreatmentVenous Thromboembolism1
2SuspendedTreatmentAnticoagulants / Aortic Valve Disease / Heart Valve Prosthesis Implantation1
2Unknown StatusPreventionHaemorrhage / Venous Thromboembolism1
2, 3RecruitingTreatmentMenstruation / Venous Thromboembolism1
2, 3Unknown StatusTreatmentStroke, Ischemic / TIA1
3Active Not RecruitingPreventionPrevention & Control1
3Active Not RecruitingPreventionVenous Thromboembolism1
3Active Not RecruitingTreatmentAntiphospholipid Syndrome1
3CompletedPreventionArthritis / Osteoarthritis, Hip / Osteoarthritis,Knee / Thromboembolism1
3CompletedPreventionEmbolism / Nonvalvular Atrial Fibrillation / Stroke1
3CompletedPreventionNonvalvular Atrial Fibrillation2
3CompletedPreventionPrevention / Venous Thromboembolism1
3CompletedPreventionProphylaxis of Pulmonary embolism / Thromboembolism / Thrombosis / Thrombosis, Venous / Venous Thromboembolism1
3CompletedPreventionVenous Thromboembolism5
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI) / Myocardial Ischemia / Unstable Angina1
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3CompletedTreatmentNonvalvular Atrial Fibrillation2
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention (PCI)1
3CompletedTreatmentPrevention / Venous Thromboembolism1
3CompletedTreatmentSuperficial Vein Thrombosis1
3CompletedTreatmentThrombosis, Venous1
3CompletedTreatmentVenous Thromboembolism1
3CompletedTreatmentProphylaxis of Pulmonary embolism2
3Not Yet RecruitingPreventionPrevention of Venous Thromboembolism1
3Not Yet RecruitingPreventionRheumatic Heart Disease2
3Not Yet RecruitingTreatmentDeep Vein Thrombosis (DVT)1
3Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
3RecruitingDiagnosticAortic Valve Stenosis / Cardiovascular Diseases / Heart Valve Diseases / Thrombosis / Ventricular Outflow Obstruction1
3RecruitingPreventionCancers / Neoplasms1
3RecruitingPreventionHeart Failure (HF) / Infectious Diseases / Respiratory Insufficiency / Rheumatic Diseases / Stroke Acute1
3RecruitingPreventionNon-major Orthopaedic Surgery1
3RecruitingPreventionNonvalvular Atrial Fibrillation1
3RecruitingPreventionPeripheral Artery Disease (PAD)1
3RecruitingPreventionStroke1
3RecruitingPreventionThrombosis1
3RecruitingPreventionTranscatheter Aortic Valve Replacement1
3RecruitingTreatmentAntiphospholipid Syndrome1
3RecruitingTreatmentCancers / Venous Thromboembolism1
3RecruitingTreatmentChronic Portal Vein Thrombosis / Deep Vein Thrombosis (DVT)1
3RecruitingTreatmentCoronary Artery Disease / Heart Failure (HF)1
3RecruitingTreatmentDeep Venous Thrombosis1
3RecruitingTreatmentHematoma1
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentMesenteric Vein Thrombosis / Portal Vein Thrombosis / Splenic Vein Thrombosis1
3RecruitingTreatmentNeoplasms / Venous Thromboembolism1
3RecruitingTreatmentRenal Insufficiency1
3RecruitingTreatmentSymptomatic Superficial Vein Thrombosis1
3RecruitingTreatmentType 2 Diabetic Patients1
3RecruitingTreatmentVenous Thromboembolism1
3TerminatedTreatmentCardiac surgery, heparin-induced thrombocytopenia and thrombosis syndrome1
3Unknown StatusPreventionVenous Thromboembolism1
4Active Not RecruitingTreatmentVenous Thromboembolism1
4Active Not RecruitingTreatmentProphylaxis of Pulmonary embolism1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedPreventionFemoral Neck Fractures / Femur Head Necrosis / Osteoarthritis, Hip1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionOsteoarthritis,Knee1
4CompletedTreatmentBleeding / Cancer-associated Thrombosis / Recurrences / Rivaroxaban1
4CompletedTreatmentBleeding / Nonvalvular Atrial Fibrillation / Stroke / Thrombo-embolism1
4CompletedTreatmentCentral Venous Catheter Thrombosis / Neoplasms1
4CompletedTreatmentChronic Renal Failure (CRF)1
4Not Yet RecruitingPreventionNonvalvular Atrial Fibrillation / Stroke1
4Not Yet RecruitingPreventionOsteoarthritis,Knee1
4Not Yet RecruitingSupportive CareProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4RecruitingNot AvailableAntiphospholipid Antibody Syndrome1
4RecruitingBasic ScienceAtrial Fibrillation or Pulmonary Embolism / Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location / Need of Long Term Oral Anticoagulation Therapy (OAT)1
4RecruitingOtherNonvalvular Atrial Fibrillation1
4RecruitingPreventionAortic Regurgitation / Aortic Stenosis / Thrombosis1
4RecruitingPreventionAtherosclerosis1
4RecruitingPreventionCalcifications, Vascular1
4RecruitingPreventionNonvalvular Atrial Fibrillation / Stroke1
4RecruitingTreatmentAnticoagulating Treatment on a Duration at Least 12-month-old Superior / Anticoagulation Treatment at Least > or = to 12-month / Permanent Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous1
4RecruitingTreatmentDiabetes1
4RecruitingTreatmentNonvalvular Atrial Fibrillation3
4TerminatedTreatmentProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Unknown StatusNot AvailableAnticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombosis1
4Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4WithdrawnTreatmentComplications; Arthroplasty1
4WithdrawnTreatmentCoronary Disease / Non ST Segment Elevation Myocardial Infarction / Stable Angina (SA) / STEMI / Unstable Angina1
Not AvailableActive Not RecruitingNot AvailableAnticoagulation1
Not AvailableActive Not RecruitingNot AvailableIschemia, Brain2
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingNot AvailableStroke, Ischemic1
Not AvailableActive Not RecruitingSupportive CareNon-valvular Atrial Fibrillation (NVAF)1
Not AvailableAvailableNot AvailableThromboembolism1
Not AvailableCompletedNot AvailableArthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee1
Not AvailableCompletedNot AvailableAtrial Fibrillation (Prevention of Stroke)1
Not AvailableCompletedNot AvailableBlood Clots1
Not AvailableCompletedNot AvailableDeep Vein Thrombosis (DVT) / Thrombosis, Venous1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation13
Not AvailableCompletedNot AvailableThrombosis, Venous2
Not AvailableCompletedNot AvailableVenous Thromboembolism3
Not AvailableNot Yet RecruitingNot AvailableSpinal Cord Injuries (SCI) / Thromboembolism1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous2
Not AvailableRecruitingNot AvailableNonvalvular Atrial Fibrillation3
Not AvailableRecruitingNot AvailableStroke1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingNot AvailableVenous Thromboembolism1
Not AvailableRecruitingNot AvailableVenous Thrombosis and Pulmonary Embolism1
Not AvailableRecruitingNot AvailableProphylaxis of Pulmonary embolism1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentDeep Venous Thrombosis1
Not AvailableUnknown StatusSupportive CareBlood Loss / Osteoarthritis, Hip1
Not AvailableUnknown StatusTreatmentIleofemoral Deep Vein Thrombosis1
Not AvailableWithdrawnNot AvailableKnee Replacement Surgery / Prophylaxis, Thromboembolism, Venous / Total Hip Replacement1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
TabletOral
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral10 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral20 mg
Tablet, film coatedOral20 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2396561 No2008-10-142020-12-11Canada
CA2547113 No2012-01-242024-11-13Canada
US7157456 No2001-02-082021-02-08Us
US7585860 No2000-12-112020-12-11Us
US7592339 No2000-12-112020-12-11Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP1.74ALOGPS
logP1.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability43.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
CarcinogenicityNon-carcinogens0.8838
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassOxazinanes
Direct ParentPhenylmorpholines
Alternative Parents
Substituents
  • Phenylmorpholine
  • 2-heteroaryl carboxamide
  • Thiophene carboxamide
  • Thiophene carboxylic acid or derivatives
  • 2,5-disubstituted thiophene
  • Aryl chloride
  • Aryl halide
  • Monocyclic benzene moiety
  • Benzenoid
  • Oxazolidinone
  • Carbamic acid ester
  • Thiophene
  • Tertiary carboxylic acid amide
  • Oxazolidine
  • Heteroaromatic compound
  • Carboxamide group
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Oxacycle
  • Azacycle
  • Organohalogen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organic oxide
  • Organochloride
  • Organonitrogen compound
  • Organooxygen compound
  • Organopnictogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [PubMed:20424181 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [PubMed:19185782 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
References
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [PubMed:20584229 ]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [PubMed:19525681 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:18 / Updated on April 29, 2017 04:37